IL-18 and MIG increase one year after transition to dolutegravir-based dual therapy despite sustained viral suppression - Scorecard - MDSpire

IL-18 and MIG increase one year after transition to dolutegravir-based dual therapy despite sustained viral suppression

  • By

  • Alexandre Pérez-González

  • Jacobo Alonso-Domínguez

  • Inés Martínez-Barros

  • Aida López-López

  • Laura Labajo-Leal

  • Antonio Ocampo

  • Eva Poveda

  • May 28, 2026

  • 0 min

Share

Clinical Scorecard: Elevated Levels of IL-18 and MIG Observed One Year After Switching to Dolutegravir-Based Dual Therapy Despite Continued Viral Suppression

At a Glance

CategoryDetail
Condition
Key MechanismsProinflammatory cytokine dynamics in virologically suppressed individuals (source needed)
Target Population
Care Setting

Key Highlights

  • Include specific data points for CD4+ count and IL-6 levels.

Guideline-Based Recommendations

Diagnosis

    Management

    • S
    • w
    • i
    • t
    • c
    • h
    • f
    • r
    • o
    • m
    • a
    • 3
    • D
    • R
    • t
    • o
    • a
    • d
    • o
    • l
    • u
    • t
    • e
    • g
    • r
    • a
    • v
    • i
    • r
    • -
    • b
    • a
    • s
    • e
    • d
    • 2
    • D
    • R
    • i
    • n
    • v
    • i
    • r
    • o
    • l
    • o
    • g
    • i
    • c
    • a
    • l
    • l
    • y
    • s
    • u
    • p
    • p
    • r
    • e
    • s
    • s
    • e
    • d
    • i
    • n
    • d
    • i
    • v
    • i
    • d
    • u
    • a
    • l
    • s
    • (
    • s
    • o
    • u
    • r
    • c
    • e
    • n
    • e
    • e
    • d
    • e
    • d
    • )

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Switching to a 2DR may not reduce inflammatory markers compared to 3DR (source needed)

        Clinical Best Practices

        • Monitor inflammatory cytokines in patients switching ART regimens (source needed)
        • Ensure virological suppression before switching from 3DR to 2DR (source needed)

        Related Resources & Content

        Original Source(s)

        IL-18 and MIG increase one year after transition to dolutegravir-based dual therapy despite sustained viral suppression

        • by Alexandre Pérez-González, Jacobo Alonso-Domínguez, Inés Martínez-Barros, Aida López-López, Laura Labajo-Leal, Antonio Ocampo, Eva Poveda

        • May 28, 2026

        Related Content

        Top 10 States With Rising Demand for Physicians

        These 10 states report physician shortages, projected physician supply gaps, or physician-to-population ratios below national benchmarks.

        Teleology of immune system response to sepsis – failure due to dysregulation or adaptive response that sometimes fails?

        To live or to die: competitive exclusion of Schistosoma japonicum by Exorchis sp. in Oncomelania hupensis